Atropine sulfate ophthalmic - Sydnexis
Alternative Names: Ryjunea; STN-1012701; SYD 101Latest Information Update: 16 Jul 2026
At a glance
- Originator Sydnexis
- Class Alcohols; Alkaloids; Antidotes; Azabicyclo compounds; Bridged bicyclo compounds; Cardiovascular therapies; Esters; Eye disorder therapies; Propanols; Small molecules; Toluenes; Tropanes
- Mechanism of Action Cholinergic receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Myopia
Most Recent Events
- 13 Jul 2026 Sydnexis announces US FDA Advisory Committee Meeting to review NDA for Myopia
- 13 Jul 2026 Sydnexis submits a Formal Dispute Resolution Request (FDRR) to the US FDA for Myopia before July 2026
- 13 Nov 2025 Efficacy and adverse events data from a phase-III trial in Myopia released by Sydnexis